Suchergebnisse - "Saxena, Kunal"

PubPharm (53)

11

PROCESS FOR PREPARATION OF PURE NALTREXONE DECANOATE, ITS SALTS, COMPOSITION AND METHOD OF USE THEREOF

enthalten in: Europäisches Patentamt | 2023

von SAXENA KUNAL | SAXENA AAKARSH

12

The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States

enthalten in: Vaccines | 2023

von Saxena, K. | Sawhney, B. | Yande, S. | +2

13

Cost-effectiveness and budget impact of heat-stable carbetocin compared to oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH) in women giving birth in India

enthalten in: BMC health services research | 2023

von Cook, J. | Saxena, K. | Taylor, C. | +1

14

Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece : Road to Recovery

enthalten in: Vaccines | 2023

von Gountas, I. | Favre-Bulle, A. | Saxena, K. | +5

15

Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway : incorporating the full health impact of all HPV-related diseases

enthalten in: Journal of medical economics | 2023

von Diakite, I. | Nguyen, S. | Sabale, U. | +5

16

Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States : a claims database study

enthalten in: Expert review of vaccines | 2023

von Eiden, A. | DiFranzo, A. | Bhatti, A. | +6

17

Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data

enthalten in: Archives of gynecology and obstetrics | 2022

von Reuschenbach, M. | Stephan, A. | Saxena, K. | +6

18

The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan

enthalten in: Value in health regional issues | 2022

von Chou, H. | Chang, S. | Sukarom, I. | +4

19

Comprimidos de naltrexona implantables

enthalten in: Europäisches Patentamt | 2022

von SAXENA NAVIN | SAXENA KUNAL

20

NON-AQUEOUS INJECTABLE COMPOSITION FOR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF

enthalten in: Europäisches Patentamt | 2022

von SAXENA KUNAL | SAXENA NAVIN